Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 1/20 | 0.65 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184994 | 0.88 | MAPT (0.65) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL3544292 | 0.87 | LMNA (0.65) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL3542181 | 0.85 | HDAC3 (0.58) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL15574146 | 0.84 | MAPT (0.61) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL26546756 | 0.83 | KDR (0.76) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL281864 | 0.82 | KDR (0.85) | TRPV1KDRPDK1 | |
| SCHEMBL13004812 | 0.80 | KDR (0.71) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL4443052 | 0.80 | KDR (0.71) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL15687774 | 0.80 | KCNJ5 (0.63) | KCNJ5KCNJ3MAPTMEN1KMT2A | |
| SCHEMBL28898825 | 0.80 | CA1 (0.74) | MAPTTRPV1KDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | DU, XIAOMIN (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | DU, XIAOMIN (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | DU, XIAOMIN (CN) | 2010-11-25 | — | — | US | disclosed |
| CN-101896460-A | Be applicable to the kinases inhibitor of treatment cancer | XIAOMIN U | 2010-11-24 | — | — | CN | disclosed |
| CN-101220024-A | A set of anti-cancer compound restraining kinase | XIAOMIN DU (CN) | 2008-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298385-A1 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS | MAP3K6, MAP3K20, MAP3K5 | KCNJ5 1862/4885KCNJ3 1941/4885MAPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.